



MINERVA FOUNDATION SYMPOSIUM 2025

FROM GENETIC OBSERVATIONS TO FUNCTIONAL INSIGHT AND THERAPY DEVELOPMENT

October 23 – 24, 2025, Hanaholmen, Espoo, Finland

Thursday 23 October

- 13:00 **Opening of the Symposium**
Vesa Olkkonen, Minerva Foundation Institute for Medical Research
- SESSION I** *Steatotic liver disease – Leveraging genetics for therapeutic insight*
- 13:05 **Chairperson Hannele Yki-Järvinen**
Minerva Foundation Institute for Medical Research
- 13:10 - 13:35 **Hepatic mitochondrial reductive stress – from genetics via bench to bedside**
Panu Luukkonen, Minerva Foundation Institute for Medical Research
- 13:40 – 14:15 **Reductive stress in steatotic liver disease – focus on GCKR**
Russell Goodman, Harvard/Massachusetts General Hospital, Boston, USA
- 14:20 – 14:55 **Intermediary metabolism in steatotic liver disease - focus on ACC**
Shawn Burgess, UT Southwestern, USA
- 15:00 – 15:20 **Functional characterization of protective gene variants in steatotic liver disease**
Sami Qadri, Minerva Foundation Institute for Medical Research
- 15:20 – 15:50 *Coffee*
- SESSION II** *Incretins –Bench to bedside*
- 15:50 **Chairperson Daniel Gordin**
Minerva Foundation Institute for Medical Research
- 15:55 – 16:30 **Incretins – Gut to brain and back**
Petter Bjornstad, University of Washington, Seattle, USA
- 16:35 – 17:10 **Incretins in patients with type 1 diabetes**
David Cherney, University of Toronto, Canada
- 17:15 – 17:50 **Incretins in the kidney guidelines 2027**
Ian de Boer, University of Washington, Seattle, USA
- 18:00 – 19:30 *Wine and snacks*

Friday 24 October

SESSION III *Bone and mineral metabolism, its genetic components and therapeutic approaches*

- 8:30 **Chairperson Heikki Koistinen**
Minerva Foundation Institute for Medical Research
- 8:35 – 9:10 **The road from the discovery of sclerostin mutations to clinical applications**
Wim van Hul, University of Antwerp, Belgium
- 9:15 – 9:50 **The clinical landscape of parathormone signaling**
Harald Jüppner, Harvard/Massachusetts General Hospital, Boston, USA
- 9:55 – 10:20 **Monogenic osteoporosis – lessons from rare phenotypes to population health problems**
Outi Mäkitie, Folkhälsan, University of Helsinki, Helsinki University Hospital, Finland
- 10:25 – 10:50 **Kidney stone disease and genetics of hypercalciuria**
Heikki Koistinen, Minerva Foundation Institute for Medical Research
- 10:50 – 11:20 *Coffee*

SESSION IV *Genetics and pharmacogenetics in personalized medicine*

- 11:20 **Chairperson Miina Ollikainen**
Minerva Foundation Institute for Medical Research
- 11:25 – 12:00 **Genetic and functional analysis of Raynaud's syndrome implicates loci in vasculature and immunity**
Hanna Ollila, FIMM, University of Helsinki and Stanford University, CA, USA
- 12:05 – 12:40 **Splicing defect as a cause of spinal muscular atrophy (SMA): Therapy with a splicing-correcting antisense oligonucleotide**
Adrian Krainer, Cold Spring Harbour Laboratory, New York, USA
- 12:40 – 13:30 *Lunch*
- 13:30 – 13:55 **Pharmacogenetics in personalized medicine**
Mikko Niemi, University of Helsinki, Finland
- 14:00 – 14:25 **Inherited infertility – mapping loci associated with impaired female reproduction**
Elisabeth Widen, FIMM, University of Helsinki, Finland
- 14:30 – 15:30 **PANEL DISCUSSION - Expensive new therapies: Who invented, who profits, who can afford?**
Moderator Sami Pakarinen, Helsinki University Hospital, Helsinki, Finland

Closing of the Symposium